Brief: Ose Immunotherapeutics’ Global License To Develop OSE-230 Becomes Effective
16/04/2024 17:17
April 16 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS’ GLOBAL LICENSE TO DEVELOP A NOVEL
MONOCLONAL ANTIBODY FOR THE TREATMENT OF CHRONIC INFLAMMATION
BECOMES EFFECTIVE
* HART-SCOTT-RODINO WAITING PERIOD HAS EXPIRED WITH RESPECT
TO ITS
GLOBAL LICENSE WITH ABBVIE ABBV.N TO DEVELOP OSE-230
* ABBVIE WILL NOW MAKE AN UPFRONT PAYMENT OF $48 MILLION TO
OSE
IMMUNOTHERAPEUTICS
* CO WILL BE ELIGIBLE TO RECEIVE UP TO ADDITIONAL $665
MILLION IN
CLINICAL DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES,
POTENTIAL TIERED ROYALTIES
Source text for Eikon: ID:nGNE10XpsK
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO